The lawsuit says the merger would solidify Novo Nordisk’s market position as a leader in the field of obesity drugs by ...

Denmark's Novo Nordisk said on Monday it is confident that its proposed takeover of U.S. drugmaker Metsera does not raise any ...

Pfizer filed an antitrust lawsuit on Monday accusing Danish drugmaker Novo Nordisk of structuring its $9 billion bid for ...

Denmark's Novo Nordisk launched a rival bid for U.S. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer ...

The Wegovy and Ozempic maker’s offer comes after Pfizer last month agreed to a lower deal to acquire the Nasdaq-listed ...

Novo Nordisk made a much higher offer to acquire a biotech Pfizer was already set to buy out. Losing this battle would be more damaging to Pfizer than to Novo Nordisk. Even so, both companies look ...

Novo Nordisk made a surprise bid for Metsera to boost its weight-loss market lead, trading at just 12x 2026 EPS. Read why NVO ...

Novo Nordisk continues to underperform the S&P 500, with a 42.5% YTD decline versus the index's 16.3% gain. Learn more about ...

Pfizer's lawsuits target Metsera, its directors, and Novo Nordisk for breach of contract and antitrust violations, focusing on Novo Nordisk's acquisition proposal. The first lawsuit claims Novo ...

This second lawsuit represents an escalation of Pfizer’s efforts to block the Danish drug giant’s $9bn offer for Metsera, ...

After filing one lawsuit to try to block Novo Nordisk's $9 billion effort to trump the takeover, Pfizer has returned to the courts with another, accusing Metsera and Novo Nordisk of anticompetitive ...

There’s plenty of reason to remain bullish on Novo Nordisk. Even with the challenges it has faced recently, the company ...